問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Family Medicine

Division of General Internal Medicine

Division of Endocrinology

Division of Cardiovascular Diseases

更新時間：2023-09-19

林文元Lin, Wen-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • D10648@mail.cmuh.org.tw

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林文元

China Medical University Hospital

Division of Family Medicine

List

28Cases

2013-11-01 - 2014-11-30

Phase III

A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy

  • Condition/Disease

    Treatment of essential hypertension inadequately controlled by monotherapy

  • Test Drug

    BAY 98-7106( Nifedipine GITS / Candesartan cilexetil fixed dose combination)

Participate Sites
5Sites

Terminated5Sites

2014-07-01 - 2016-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-10-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-12-19 - 2018-12-31

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of CBW-511, a Botanical Drug Containing Catechins and Curcuminoids, in Overweight and Obese Patients

  • Condition/Disease

    Overweight and Obesity

  • Test Drug

    CBW-511

Participate Sites
4Sites

Terminated4Sites

2023-01-30 - 2024-12-29

Phase II

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  • Condition/Disease

    Type 2 Diabetes Mellitus、Obesity、Overweight

  • Test Drug

    AMG133

Participate Sites
4Sites

Recruiting4Sites

2020-01-01 - 2024-08-08

Phase III

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

  • Condition/Disease

    Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities

  • Test Drug

    Tirzepatide

Participate Sites
5Sites

Terminated5Sites

2012-08-01 - 2013-12-31

Phase I

A randomized, double-blind, placebo controlled, crossover study to assess safety and tolerability, pharmacokinetics, and explore pharmacodynamics of TAP311 in patients with mixed dyslipidaemia

  • Condition/Disease

    mixed dyslipidaemia

  • Test Drug

    TAP311

Participate Sites
1Sites

Terminated1Sites

2012-12-01 - 2016-08-31

Phase II

A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure in elderly patients with essential hypertension.

  • Condition/Disease

    ESSENTIAL HYPERTENSION

  • Test Drug

    LCZ696

Participate Sites
3Sites

Terminated3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB